Novo Nordisk A/S
NVO
$49.16
-$1.10-2.19%
NYSE
Recommendation
Prev Close
Volume
Avg Vol (90D)
Market Cap
Dividend & Yield
P/E (TTM)
EPS (TTM)
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 46.70B | 45.46B | 43.59B | 42.09B | 39.35B |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 46.70B | 45.46B | 43.59B | 42.09B | 39.35B |
| Cost of Revenue | 8.30B | 7.16B | 6.69B | 6.32B | 5.97B |
| Gross Profit | 38.40B | 38.30B | 36.90B | 35.77B | 33.38B |
| SG&A Expenses | 10.75B | 10.48B | 9.94B | 9.76B | 9.55B |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -104.23M | -89.35M | -151.29M | -66.61M | -5.46M |
| Total Operating Expenses | 25.62B | 23.83B | 22.48B | 21.82B | 21.00B |
| Operating Income | 21.07B | 21.63B | 21.11B | 20.27B | 18.36B |
| Income Before Tax | 19.44B | 20.51B | 19.03B | 18.45B | 17.36B |
| Income Tax Expenses | 4.15B | 4.33B | 3.98B | 3.80B | 3.57B |
| Earnings from Continuing Operations | 15.30K | 16.18K | 15.05K | 14.65K | 13.79K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 15.30B | 16.18B | 15.05B | 14.65B | 13.79B |
| EBIT | 21.07B | 21.63B | 21.11B | 20.27B | 18.36B |
| EBITDA | 23.00B | 23.35B | 22.48B | 21.42B | 19.47B |
| EPS Basic | 3.44 | 3.64 | 3.38 | 3.29 | 3.09 |
| Normalized Basic EPS | 2.95 | 3.00 | 2.91 | 2.82 | 2.59 |
| EPS Diluted | 3.44 | 3.64 | 3.38 | 3.28 | 3.09 |
| Normalized Diluted EPS | 2.95 | 3.00 | 2.90 | 2.82 | 2.58 |
| Average Basic Shares Outstanding | 17.77B | 17.78B | 17.80B | 17.82B | 17.83B |
| Average Diluted Shares Outstanding | 17.80B | 17.81B | 17.83B | 17.85B | 17.87B |
| Dividend Per Share | 1.70 | 1.70 | 1.63 | 1.63 | 1.43 |
| Payout Ratio | 49.60% | 44.93% | 48.33% | 44.06% | 46.82% |